AI capability has never been higher, yet most pharma AI programmes are still failing to create measurable business impact. In this solo episode, Dr Andree Bates breaks down why many pharma and biotech AI strategies are “broken before they even begin” and what a real AI strategic blueprint needs to include if you want adoption, scale, and outcomes, not just impressive pilots.

Dr Andree explains the core paradox: AI can now synthesise literature at speed, accelerate discovery, and outperform human experts in specific tasks, but the business results are often disappointing because the failure is rarely technical. It is strategic. She describes the “technical obsession trap”, where organisations spend months optimising models and benchmarking competitors while adoption remains low and teams are not operationally ready to act on the outputs.

She outlines three common failure modes:

Innovation Theatre, where disconnected pilots never compound into enterprise value
Competitor benchmarking, where companies copy use cases that do not fit their context
Technology first strategy, where tools are bought before priorities are defined

From there, she maps what a strong pharma AI blueprint must cover: grounding in business objectives, end to end deployment architecture (data, governance, capability, change), leadership and culture, rigorous financial modelling tied to revenue and ROI, and alignment across functions including commercial, medical, regulatory, R&D, market access, insights, and tech teams.

Dr Andree closes with a clear challenge for leadership: competitive advantage will come to organisations that build the most intelligent operating model around AI, not those with the biggest budgets. She also offers a free 45 minute AI strategic diagnostic for pharma and biotech leaders who want an honest read on what to fix before investing further.

Topics Covered

Why pharma AI impact often disappoints despite powerful tools
The “technical obsession trap” and the AI strategy blind spot
Innovation Theatre, competitor benchmarking, and technology first mistakes
What a pharma AI strategic blueprint must include
Governance as a foundation for scale and regulatory trust
Leadership, culture, and adoption as the real differentiators
Financial modelling and prioritisation based on ROI and revenue impact
Organisational alignment across the full pharma value chain
Choosing the right advisory partner and avoiding generic frameworks
Why strategy must come before technology to build durable advantage

AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.

This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.

Dr. Andree Bates LinkedIn | Facebook | X

EP206: Why Your Pharma AI Strategy Is Probably Broken — And What a Real Blueprint Looks Like

AI For Pharma Growth

EP206: Why Your Pharma AI Strategy Is Probably Broken — And What a Real Blueprint Looks Like